Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: stable financial performance with a decrease in net loss and increased FYARRO sales, but ongoing financial challenges and risks from clinical trials. The Q&A section highlights management's uncertainty in key areas, like TSC1 and 2 expectations, and vague responses on sales potential, which may concern investors. Despite positive cash flow and a promising market opportunity, uncertainties in trial outcomes and market adoption, along with lack of guidance, suggest a neutral short-term stock price movement.
Key Financial Performance
FYARRO Product Sales $6.2 million for Q2 2024, in line with the prior year period and up 15% over Q1 2024. Growth was driven by a 14% increase in the number of ordering accounts compared to Q1.
Cumulative Sales of FYARRO $51.1 million since launch in February 2022.
Cash, Cash Equivalents and Short-term Investments $78.6 million at the end of Q2 2024, supporting operations into Q4 2025.
Research and Development Expenses $13.1 million for Q2 2024, compared to $13.3 million in Q2 2023, reflecting continued progress in ongoing trials.
Selling, General and Administrative Expenses $7.9 million for Q2 2024, down from $11.8 million in Q2 2023, due to reduced commercial, marketing, and personnel expenses.
Net Loss $14.6 million for Q2 2024, compared to $18 million in Q2 2023, indicating improved financial performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FYARRO Sales: FYARRO product sales were $6.2 million for Q2 2024, consistent with the prior year and up 15% from Q1. Cumulative sales since launch in February 2022 reached $51.1 million.
Market Opportunity for nab-sirolimus: The projected market opportunity for TSC1 and TSC2 mutated cancers is estimated to be between $300 million to $600 million in the U.S. alone.
PRECISION1 Trial Enrollment: The PRECISION1 trial is fully enrolled with 120 patients and is expected to complete by the end of 2024.
Clinical Trials: Aadi is evaluating nab-sirolimus in advanced endometrial cancer and neuroendocrine tumors, with initial data expected later this year.
Strategic Focus: Aadi is focused on expanding nab-sirolimus into larger indications across multiple types of mTOR driven tumors.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that actual events or results could differ materially from forward-looking statements due to various risks, uncertainties, and factors, including regulatory issues related to the approval of nab-sirolimus.
Market Competition: Aadi is focused on a competitive landscape where they aim to establish nab-sirolimus as a preferred treatment option, facing pressures from existing mTOR inhibitors and other therapies.
Clinical Trial Risks: The success of the PRECISION1 trial is critical, and any adverse outcomes or delays in the trial could impact the company's ability to submit for FDA approval.
Financial Risks: The company reported a net loss of $14.6 million for Q2 2024, indicating ongoing financial challenges that could affect future operations and investments.
Supply Chain Challenges: While not explicitly mentioned, the ongoing economic factors and potential supply chain disruptions could impact the availability and distribution of nab-sirolimus.
Market Adoption: The anticipated market adoption of nab-sirolimus is contingent on the results of clinical trials and the willingness of oncologists to utilize the drug in later treatment lines.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Sales of FYARRO: Achieved $51.1 million in cumulative sales since launch in February 2022.
PRECISION1 Trial: Fully enrolled with 120 patients; expected interim readout in Q3 2024.
Market Opportunity: Projected market opportunity for TSC1 and TSC2 mutated cancers is $300 million to $600 million in the U.S.
Cash Runway: Cash runway anticipated to extend into Q4 2025.
Q2 2024 FYARRO Sales: Product sales were $6.2 million, up 15% over Q1.
R&D Expenses: R&D expenses for Q2 amounted to $13.1 million.
Net Loss: Net loss for Q2 was $14.6 million, improved from $18 million in Q2 2023.
Future Data Releases: Expect to provide interim analysis from PRECISION1 later this quarter and initial data from EEC and NET trials by year-end.
FDA Filing: If data from PRECISION1 continues to hold, a filing with the FDA is anticipated in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cumulative Sales of FYARRO: Since launch in February 2022, Aadi Bioscience has achieved $51.1 million in cumulative sales of FYARRO.
Q2 FYARRO Product Sales: FYARRO product sales were $6.2 million for the second quarter of 2024, in line with the prior year period and up 15% over Q1.
Cash Position: Aadi ended the second quarter of 2024 with $78.6 million in cash, cash equivalents, and short-term investments.
Net Loss: The net loss for the second quarter was $14.6 million, compared to $18 million in the second quarter of 2023.
Projected Market Opportunity: The projected market opportunity for TSC1 and TSC2 mutated cancers is estimated to be between $300 million to $600 million in the U.S. alone.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What kind of expectation do you have for TSC1 and 2 based on the first interim data?
A:We wouldn't draw any anticipation in terms of the direction of which we see that data going at this point in time. We'll have to wait for that report to see that.
Q:What will be the key topic in the discussion with the FDA regarding the second interim data?
A:We do think this would be a good foundation for data-driven discussion with the FDA on a potential path to submission.
Q:What should we expect from the initial data update for the EEC and NET studies later this year?
A:By the end of the year, we will be able to give a fairly full summer report on the first cohort of patients and probably some partial information on the second cohort.
Q:Is there any scenario in which the design and execution of the remainder of PRECISION1 is altered?
A:At this point, we don't anticipate any adjustments to the trial given the trajectory that we've seen so far.
Q:What are your expectations for FYARRO's growth?
A:We remain very positive on the outlook for continued incremental growth in the business in Q3 and Q4 of this year.
Q:Is there any particular tumor type that you're favoring for future trials?
A:This is truly a tumor-agnostic trial. We don't anticipate or guide this trial PRECISION1 towards any specific tumor types.
Q:Are you planning to disclose data on earlier lines of treatment in the next data release?
A:That would be a decision that's highly data dependent in terms of what we actually see from the patient population.
Q:What are you looking for from the Phase II program in neuroendocrine tumors regarding efficacy and safety?
A:We don't have enough information to know which of the subset NET is going to have a better response rate.
Q:What is your updated view on maximum sales potential for PEComas in the U.S.?
A:It's hard to predict exactly where that can land over time.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific expectations for TSC1 and 2 based on the first interim data, stating they would have to wait for the report. Additionally, they provided vague responses about the maximum sales potential for PEComas, indicating it is hard to predict.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aadi Bioscience
EEC NET
FDA
NGS testing
PFS
Slide
Sure
account
approach
approval
benefit
cohort patient
comparison
demand
demographic
design
disease
endpoint
excitement
expectation
idea
kind
letrozole
line treatment
nab sirolimus
path
physician
platinum paclitaxel
population
product
reaction
segment
setting
sort
stage
survival
testing specialty
trial patient
tumor trial
AADI Transcript
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call presents a mixed picture: stable financial performance with a decrease in net loss and increased FYARRO sales, but ongoing financial challenges and risks from clinical trials. The Q&A section highlights management's uncertainty in key areas, like TSC1 and 2 expectations, and vague responses on sales potential, which may concern investors. Despite positive cash flow and a promising market opportunity, uncertainties in trial outcomes and market adoption, along with lack of guidance, suggest a neutral short-term stock price movement.
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. Financial performance shows positive revenue growth and a strong cash position, but there are concerns about increased R&D expenses and net losses. The Q&A highlights ongoing trials with some promising interim results, but uncertainties remain about future trial outcomes and competitive pressures. Management's reluctance to provide specific guidance on FYARRO sales adds to the uncertainty. Overall, these factors suggest a neutral stock price movement in the short term.
Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript
Unknown11-8
The earnings call highlights several concerns: increasing net loss, high R&D and SG&A expenses, and heavy reliance on a single product (FYARRO). While FYARRO sales grew, they remain modest, and commercialization challenges persist. The PRECISION 1 trial carries significant risks, and management was vague in the Q&A, avoiding specifics on key trial details. Despite having cash reserves, the financial and clinical uncertainties overshadow positive aspects, leading to a negative sentiment.
Aadi Bioscience, Inc. (AADI) Q2 2023 Earnings Call Transcript
Neutral8-9
AADI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
